摘要
目的分析比较罗氏和诺华核酸试剂的核酸检测(NAT)能力。方法同时运用罗氏和诺华系统对262例无偿献血者血液标本及10例卫生部室间质评(NCCL)核酸标本进行检测,统计分析比较阳性检测率。结果 245例酶联免疫吸附实验(ELISA)检测阴性的献血者标本中,罗氏和诺华系统分别检出1例和4例NAT阳性,其中仅有诺华1例鉴别实验鉴别为HBV,其余均未能鉴别;17例ELISA检测阳性的标本中,运用罗氏系统检测,11例HBs Ag阳性的标本检出5例NAT阳性,5例抗-HCV阳性的标本检出3例,1例抗-HIV阳性的标本未检出,10例NCCL标本全部正确检出;运用诺华系统检测,上述ELISA阳性标本分别检出3例、3例和0例,NCCL标本也全部正确检出。结论两种核酸检测系统在检测能力上各有优势,均能较好地胜任日常的检测工作。
Objective To analyze and compare the detection ability of nucleic acid reagent of Roche and Novartis. Methods Roche and Novartis nucleic acid detection systems were used to detect the 262 specimens of blood donors and 10 copies of NCCL specimens, the positive detection rates of the two systems were statistically analyzed. Results Among 245 cases of blood specimens with negative NAT detected by ELISA, Roche and Novartis systems detected 1 case and 4 cases with positive NAT respectively. In the identification test, only one of the NAT positive specimens detected by Novartis system was identified as HBV. In the17 cases of blood specimens with positive NAT detected by ELISA, when detected by Roche system, 11 cases of HBs Ag positive specimens had 3 cases with positive NAT, 5 cases of anti-HCV positive specimens had 3 cases with positive NAT. In 1 case of anti-HIV positive specimens, the NAT was negative, 10 cases of NCCL specimens were correctly detected, while using Novartis systems to detect, among HBs Ag positive specimens, anti-HCV positive specimens and anti- HIV positive specimens, there were3 cases, 3 cases and 0 case of them with positive NAT, NCCL specimens were also correctly detected. Conclusion Two kinds of nucleic acid detection system have their own advantages in detection capability, both of them can be well fit for routine tests.
出处
《实验与检验医学》
CAS
2015年第1期43-45,共3页
Experimental and Laboratory Medicine
关键词
NAT
罗氏核酸检测系统
诺华核酸检测系统
血液筛查
NAT
Roche nucleic acid detection system
Novartis nucleic acid detection system
Blood screening
